R. Wagman et al., SPHINCTER PRESERVATION IN RECTAL-CANCER WITH PREOPERATIVE RADIATION-THERAPY AND COLOANAL ANASTOMOSIS - LONG-TERM FOLLOW-UP, International journal of radiation oncology, biology, physics, 42(1), 1998, pp. 51-57
Citations number
20
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Background: To determine if preoperative radiation therapy allows sphi
ncter preservation in the treatment of rectal cancer. Methods: Thirty
six patients with the diagnosis of invasive, resectable, primary adeno
carcinoma of the rectum limited to the pelvis were enrolled on a Phase
I/II trial of preoperative radiation therapy plus low anterior resect
ion/coloanal anastomosis. By preoperative assessment, all patients had
invasive tumors (5,T-2,T- 31,T-3) involving the distal half of the re
ctum and clinically required an abdominoperineal resection. The median
tumor size was 3.8 cm [range: 1.5-7 cm] and the median distance from
the anal verge was 4 cm [range: 3-7 cm]. The whole pelvis received 46.
80 Gy followed by a 3.60 Gy boost to the primary tumor bed. The median
follow-up was 56 months [range: 4-121 months]. Results: Of the 35 pat
ients who underwent resection, 5 (14%) had a complete pathologic respo
nse and 27 (77%) were able to successfully undergo a low anterior rese
ction/coloanal anastomosis. The incidence of local failure was crude:
17% and 5-year actuarial: 21%. The 5-year actuarial survival was 64%.
Analysis of sphincter function using a previously published scale was
performed at the time of last follow-up in the 27 patients who underwe
nt a low anterior resection/coloanal anastomosis. Function was good or
excellent in 85%. The median number of bowel movements/day was 2 (ran
ge: 0-8). Conclusions: Our data suggest that preoperative radiation th
erapy allows sphincter preservation in 77% of selected patients who wo
uld otherwise require an abdominoperineal resection, and 85% have good
to excellent sphincter function. Given the moderate local failure rat
e, we now routinely use preoperative combined modality therapy plus po
stoperative chemotherapy for patients with clinical T-3 disease. (C) 1
998 Elsevier Science Inc.